DFDA

Combination Intranasal Corticosteroid + Antihistamine

Treatment for Allergic Rhinitis

Typical Dosage: 1 spray per nostril twice daily (e.g., Azelastine/Fluticasone)

Effectiveness
92%
Safety Score
75%
Clinical Trials
4
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
1 spray per nostril twice daily (e.g., Azelastine/Fluticasone)
Time to Effect
15-30 minutes for initial, few days for full effect
Treatment Duration
Seasonal or daily as needed
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$900
Monitoring:$25
Side Effect Mgmt:$20
Total Annual:$945
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$75,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$1,111.76
Cost per Remission
$1,890
Comparison vs Intranasal Corticosteroids
Cost Difference
+$730/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$565
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$75/year
Travel + wait time
Insurance Admin Cost
$40/year
Prior auth, claims
Rx Price
$900/year
Potential OTC Price
$600/year
Estimated if OTC available
Early Treatment Benefit
+0.03 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Combination Intranasal Corticosteroid + Antihistamine Outcomes

for Allergic Rhinitis

Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+85%
Remission Rate
+50%
Common Side Effects
Bitter taste/dysgeusia
+20%
Nasal irritation/epistaxis
+15%
Headache
+8%
Drowsiness
+3%

Sources:

nih.gov
nih.gov
ekb.eg

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
4 active trials recruiting for Combination Intranasal Corticosteroid + Antihistamine in Allergic Rhinitis

A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms

NCT07294326NOT YET RECRUITINGPHASE4
View Study
50 participants
INTERVENTIONAL
Started: Jan 1, 2026

Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis

NCT05348148RECRUITINGNA
View Study
450 participants
INTERVENTIONAL
Luodong, Taiwan
Started: Jun 16, 2020

Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis

NCT05080322RECRUITINGPHASE4
View Study
150 participants
INTERVENTIONAL
Wuhan, China
Started: Sep 9, 2021

Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis

NCT07115342RECRUITINGNA
View Study
120 participants
INTERVENTIONAL
Tanta, Egypt
Started: Aug 1, 2025
Completed Clinical Trials
1 completed trial for Combination Intranasal Corticosteroid + Antihistamine in Allergic Rhinitis

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195COMPLETEDPHASE4
View Study
150 participants
INTERVENTIONAL
Fort Worth, United States
Started: Mar 1, 2009